Clinical Trials Sponsored by Aprea Therapeutics

Total 6443 results

Aprea Therapeutics

Recruiting

Study Of ATRN-119 In Patients With Advanced Solid Tumors (ABOYA-119)

Advanced Solid Tumor

United States
Aprea Therapeutics

Completed

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

MDS

United States, France
Aprea Therapeutics

Completed

Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies

Gastric Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma

United States
Aprea Therapeutics

Completed

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Myeloid Malignancy

United States
Aprea Therapeutics

Not yet recruiting

Study of APR-1051 in Patients With Advanced Solid Tumors (ACESOT-1051)

Advanced Solid Tumor
Aprea Therapeutics

Completed

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia or Myelodysplastic Syndromes

United States
Aprea Therapeutics

Completed

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

United States, France, Spain, Netherlands, United Kingdom, Belgium, Germany, Sweden
Aprea Therapeutics

Completed

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

High-grade Serous Ovarian Cancer

Spain, United Kingdom, Belgium
Aprea Therapeutics

Terminated

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (R/R)

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
Aprea Therapeutics

Terminated

APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | MDS

United States
Aprea Therapeutics

Completed

Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer

Prostatic Neoplasms | Hematologic Neoplasms

Sweden
Aprea Therapeutics
Jules Bordet Institute

Terminated

A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma

Melanoma

Belgium
Groupe Francophone des Myelodysplasies
Aprea Therapeutics

Unknown

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Chronic Myelomonocytic Leukemia | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Gene Mutations | Myelodysplastic Syndrome With Gene Mutation

France
H. Lee Moffitt Cancer Center and Research Institute
Aprea Therapeutics

Completed

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm

United States
Apreo Health, Inc.

Recruiting

Study to Assess Safety, Feasibility, and Preliminary Efficacy of the Apreo Implant for Severe Emphysema (BREATHE-2)

Emphysema or COPD

United Kingdom, Austria, Netherlands
Apreo Health, Inc.

Recruiting

First in Human Study to Assess an Implant to Treat Severe Emphysema (BREATHE-1)

Emphysema or COPD

Australia
Sault Area Hospital

Completed

Topical Tranexamic Acid (TXA) in Hip Fractures

Anemia | Hip Fracture

Canada
Craigavon Area Hospital

Unknown

The Low HDL On Six Weeks Statin Therapy (LOW) Study

Coronary Arteriosclerosis | HDL Cholesterol | Lipoproteins

United Kingdom
Bay Area Gynecology Oncology

Unknown

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy (HIPEC/IPHC)

Cervical Cancer | Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Uterine Cancer | Gastrointestinal Cancers | Mesotheliomas

United States
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
Saskatchewan Health Authority - Regina Area

Not yet recruiting

Safety and Efficacy of an Oral Penicillin Challenge in Low Risk Hospitalized Patients

Penicillin Allergy
Saskatchewan Health Authority - Regina Area

Withdrawn

Reducing Unnecessary Antibiotic Prescriptions in Primary Healthcare in Saskatchewan by Identifying High Prescribers

Upper Respiratory Tract Infections
Saskatchewan Health Authority - Regina Area

Completed

Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms (TARAA)

Abdominal Aortic Aneurysms

Canada
Saskatchewan Health Authority - Regina Area

Completed

The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section

Surgical Wound Infection

Canada
Woman's
Baton Rouge Area Foundation

Completed

Insulin Action During Pregnancy in Woman at High Risk for Gestational Diabetes (DRM)

Gestational Diabetes Mellitus

United States
Wentworth Area Health Services
Abbott

Unknown

Levosimendan Versus Dobutamine in Shock Patients

Septic Shock | Cardiogenic Shock

Australia
Saskatchewan Health Authority - Regina Area

Active, not recruiting

Fundal Block in Pre-menopausal Women to Reduce Pain During Outpatient-based Endometrial Ablation (FUNDAL-PAIN) (FUNDAL-PAIN)

Pain

Canada
Saskatchewan Health Authority - Regina Area

Completed

Renal Denervation in Patients With Chronic Kidney Disease

Chronic Kidney Disease

Canada
Saskatchewan Health Authority - Regina Area

Withdrawn

Opioid Reduction Following Spinal Cord Stimulation (REDUCE)

Chronic Pain

Canada
Saskatchewan Health Authority - Regina Area

Completed

The Effect of Birth Plans on Obstetrical Outcomes

Pregnancy

Canada
Saskatchewan Health Authority - Regina Area

Completed

Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence

Urinary Urge Incontinence

Canada
Mountain Area Health Organization Center

Unknown

Randomized Controlled Trial of Bladder Flap vs.None

Cesarean Delivery Procedures

United States
Bay Area Retina Associates
Allergan

Recruiting

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (STAMP)

Diabetic Macular Edema | Cataract

United States
Saskatchewan Health Authority - Regina Area

Completed

Airway Pressure Release Ventilation for Moderate-to-severe Acute Respiratory Distress Syndrome (EARL)

Acute Respiratory Distress Syndrome

Canada
Saskatchewan Health Authority - Regina Area

Completed

Improving Prostate Cancer Detection Using MRI-Targeted TRUS-Guided Biopsy

Prostate Cancer

Canada
Saskatchewan Health Authority - Regina Area

Completed

Randomized Controlled Trial: Induction of Labour of Obese Women With Dinoprostone or Single Balloon Catheter

Obesity | Pregnancy | Labor, Induced

Canada
Saskatchewan Health Authority - Regina Area

Completed

Prostatic Artery Embolization for Benign Prostatic Hyperplasia

Benign Prostate Hyperplasia

Canada
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

Clear Cell Renal Cell Carcinoma | Pancreatic Adenocarcinoma | Cervical Carcinoma | Malignant Pleural Mesothelioma | Esophageal Carcinoma

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

T Cell Lymphoma

United States, Australia, Canada
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)

B-cell Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Adult B Cell ALL

United States, Spain, Canada, France, Germany, Australia
Bacainn Therapeutics, Inc.

Completed

A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects

Healthy Volunteers

United States
Celsus Therapeutics PLC

Terminated

Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% (C012013)

Atopic Dermatitis

Israel
Eikon Therapeutics
Impact Therapeutics, Inc.

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Advanced Solid Tumor

Australia, United States
APRINOIA Therapeutics, LLC

Active, not recruiting

A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants

Alzheimer Disease | Tauopathies | Healthy Volunteers

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

Renal Cell Carcinoma

United States, Australia, Canada, Netherlands
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
CRISPR Therapeutics AG

Enrolling by invitation

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Hematologic Malignancy | Solid Malignancy

United States
CRISPR Therapeutics AG

Active, not recruiting

A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Australia, Canada

Clinical Trials Sponsored by Aprea Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations